Valeant Pharmaceuticals International, Inc. appointed Louis W. Yu, PhD to the newly created position of Chief Quality Officer, Global Quality, effective October 3, 2016. Dr. Yu reports to Joseph C. Papa, Chairman and CEO of Valeant.  As a new member of Valeant's Executive Committee, Dr. Yu will oversee all aspects of quality and regulatory compliance for all of Valeant's global businesses and operating sites.

Dr. Yu joins Valeant with more than 30 years of leadership experience in the Quality and R&D functions of generic and branded pharmaceutical companies. He was Executive Vice President, Global Quality & Compliance at The Perrigo Company from November 2006 to January 2016, where he was responsible for strategic leadership and regulatory compliance as well as the global patient safety/medical affairs departments.  He also served between May and September 2016 as the Senior Vice President, Global Quality and Compliance at AMRI, a contract development and manufacturing organization (CDMO) company.

"Delivering quality products leads to quality health outcomes, and that is what we are focused on at Valeant," said Joseph C. Papa, chief executive officer of Valeant. "Dr. Louis Yu is a great addition to our organization, and we are delighted to bring him into the company in the important new role of Chief Quality Officer. Dr. Yu's deep quality leadership experience at a number of branded and generic pharmaceutical companies gives him a deep understanding of what our customers and regulators need, and I look forward to working closely with him."

Dr. Yu said, "I appreciate the opportunity to lead Valeant's global quality function and am eager to help the company implement sustainable quality and compliance programs that will further strengthen its businesses."